JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma.
JNJ-49095397 (RV568) (1 pg-1 μg/mL; 4 h) inhibits LPS-induced CXCL8 release in PBMCs and d-U937 cells[1].
JNJ-49095397 (1 μg-1 g/mL; 4 h) inhibits TNFα-induced interleukin (IL)-6 and CXCL8 release in a concentration-dependent manner[1].
JNJ-49095397 (RV568) (1-20 μg/mouse; intratracheal; once) shows anti-inflammatory activities in LPS-induced neutrophil accumulation mouse model[1].
















